NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free FOLD Stock Alerts $9.50 -0.16 (-1.66%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$9.29▼$9.6350-Day Range$9.04▼$12.3052-Week Range$9.02▼$14.57Volume2.51 million shsAverage Volume3.01 million shsMarket Capitalization$2.81 billionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amicus Therapeutics alerts: Email Address Amicus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside84.2% Upside$17.50 Price TargetShort InterestHealthy9.71% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.35Based on 25 Articles This WeekInsider TradingSelling Shares$176,025 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.12) to $0.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.39 out of 5 starsMedical Sector126th out of 929 stocksPharmaceutical Preparations Industry44th out of 433 stocks 4.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amicus Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.71% of the outstanding shares of Amicus Therapeutics have been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Amicus Therapeutics has recently decreased by 8.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmicus Therapeutics has received a 63.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Fabry disease medication", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Amicus Therapeutics is -1.28. Previous Next 1.9 News and Social Media Coverage News SentimentAmicus Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Amicus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for FOLD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,025.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($0.12) to $0.23 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -19.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 21.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaA ‘DeFi Summer’ Projected!Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x!Just click here to learn how you can access this coin right now. About Amicus Therapeutics Stock (NASDAQ:FOLD)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More FOLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FOLD Stock News HeadlinesMay 4, 2024 | insidertrades.comInsider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,500 Shares of StockMay 16 at 4:28 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by GuggenheimMay 14 at 5:59 PM | msn.comGuggenheim Upgrades Amicus Therapeutics (FOLD)May 14 at 5:59 PM | markets.businessinsider.comEvaluating Amicus Therapeutics: Insights From 6 Financial AnalystsMay 14 at 7:06 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Given New $19.00 Price Target at Morgan StanleyMay 14 at 4:34 AM | americanbankingnews.comNeedham & Company LLC Reiterates "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD)May 14 at 2:08 AM | americanbankingnews.comBank of America Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $13.00May 13 at 1:48 AM | americanbankingnews.comAnalysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $20.00May 12, 2024 | americanbankingnews.comUBS Group Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $19.00May 10, 2024 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...May 10, 2024 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | investorplace.comFOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | washingtonpost.comAmicus Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAmicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comAmicus Therapeutics to Present at the Bank of America 2024 Health Care ConferenceMay 8, 2024 | americanbankingnews.comAmicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2024 | barrons.comAmicus Therapeutics Inc.May 1, 2024 | globenewswire.comAmicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024April 14, 2024 | nasdaq.comAmicus Therapeutics Becomes Oversold (FOLD)March 30, 2024 | msn.comNevada’s Lee joins on to Amicus Brief in SCOTUS abortion caseMarch 29, 2024 | msn.comNevada’s Lee, Cortez Masto join on to Amicus Brief in SCOTUS abortion caseMarch 20, 2024 | globenewswire.comAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) ReportMarch 16, 2024 | ca.finance.yahoo.comFOLD Jul 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Oct 2024 12.000 callMarch 7, 2024 | finance.yahoo.comFOLD Jan 2025 12.000 putSee More Headlines Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/16/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees517Year Founded2002Price Target and Rating Average Stock Price Target$17.50 High Stock Price Target$22.00 Low Stock Price Target$13.00 Potential Upside/Downside+84.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,580,000.00 Net Margins-34.73% Pretax Margin-33.17% Return on Equity-77.08% Return on Assets-13.79% Debt Debt-to-Equity Ratio2.97 Current Ratio3.03 Quick Ratio2.61 Sales & Book Value Annual Sales$399.36 million Price / Sales7.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book21.59Miscellaneous Outstanding Shares296,200,000Free Float289,683,000Market Cap$2.81 billion OptionableOptionable Beta0.80 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Bradley L. Campbell M.B.A. (Age 48)CEO, President & Director Comp: $984.09kMs. Ellen S. Rosenberg (Age 61)Chief Legal Officer & Corporate Secretary Comp: $733.94kMr. David M. Clark (Age 49)Chief People Officer Comp: $701.39kDr. Jeffrey P. Castelli (Age 52)Chief Development Officer Comp: $709.64kMr. Simon Nicolas Reade Harford (Age 64)Chief Financial Officer Ms. Samantha Prout (Age 46)Chief Accounting Officer & Controller Dr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerMs. Diana MooreHead of Global Corporate CommunicationsMore ExecutivesKey CompetitorsGeronNASDAQ:GERNTurning Point TherapeuticsNASDAQ:TPTXLigand PharmaceuticalsNASDAQ:LGNDDynavax TechnologiesNASDAQ:DVAXPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 2,307,385 shares on 5/16/2024Ownership: 4.664%Redmile Group LLCSold 1,571,035 shares on 5/16/2024Ownership: 4.476%Silvercrest Asset Management Group LLCBought 16,033 shares on 5/16/2024Ownership: 0.127%Bayesian Capital Management LPBought 50,200 shares on 5/16/2024Ownership: 0.017%Public Employees Retirement Association of ColoradoSold 1,522 shares on 5/15/2024Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions FOLD Stock Analysis - Frequently Asked Questions Should I buy or sell Amicus Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares. View FOLD analyst ratings or view top-rated stocks. What is Amicus Therapeutics' stock price target for 2024? 7 analysts have issued twelve-month price objectives for Amicus Therapeutics' stock. Their FOLD share price targets range from $13.00 to $22.00. On average, they anticipate the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 84.2% from the stock's current price. View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts. How have FOLD shares performed in 2024? Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD stock has decreased by 33.1% and is now trading at $9.50. View the best growth stocks for 2024 here. When is Amicus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our FOLD earnings forecast. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.04. The biopharmaceutical company had revenue of $110.40 million for the quarter, compared to the consensus estimate of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative trailing twelve-month return on equity of 77.08%. Amicus Therapeutics's revenue for the quarter was up 27.9% on a year-over-year basis. During the same period last year, the company posted ($0.18) EPS. What ETFs hold Amicus Therapeutics' stock? ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Sovereigns Capital Flourish Fund (SOVF), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).iShares Biotechnology ETF (IBB). What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $499.2 million-$519.2 million, compared to the consensus revenue estimate of $530.0 million. What is John F. Crowley's approval rating as Amicus Therapeutics' CEO? 21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Janus Henderson Group PLC (4.66%), Redmile Group LLC (4.48%), William Blair Investment Management LLC (3.89%), Healthcare of Ontario Pension Plan Trust Fund (0.73%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FOLD) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
